Ganciclovir

Generic Name: Ganciclovir

Brand Names: Cytovene, Zirgan

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₅O_₄

CAS Number: 82410-32-0

Unique Ingredient Identifier: P9G3CKZ4P5

Background: An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.

Indication: For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.

Associated Conditions: CMV colitis, Cytomegalovirus (CMV) Infections, Cytomegalovirus Retinitis, Cytomegalovirus gastroesophagitis, Varicella-zoster Progressive outer retinal necrosis, Acute Herpetic keratitis, Cytomegalovirus neurological disease, Varicella-zoster virus acute retinal necrosis

Clinical Trials

Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation

Phase 3

Completed

Conditions: Infection

First Posted Date: 2003-01-27

Last Posted Date: 2010-05-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 184

Registration Number: NCT00016068

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
University of Florida Shands Cancer Center, Gainesville, Florida, United States

and more 4 locations

Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus

Phase 1

Completed

Conditions: Leukemia
Lymphoma
Precancerous Condition
Small Intestine Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-26

Lead Sponsor: Boston Medical Center

Registration Number: NCT00006340

Locations: 🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
🇺🇸
Cancer Research Center at Boston Medical Center, Boston, Massachusetts, United States
🇮🇹
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy

and more 3 locations

Valganciclovir in Congenital CMV Infants

Phase 1

Completed

Conditions: Cytomegalovirus Infections

Interventions: Drug: Valganciclovir
Drug: Ganciclovir

First Posted Date: 2002-03-07

Last Posted Date: 2011-02-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT00031434

Locations: 🇺🇸
University of Louisville, Louisville, Kentucky, United States
🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States
🇺🇸
Cook Children's Medical Center, Fort Worth, Texas, United States

and more 18 locations

A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic Therapy

Phase 1

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 38

Registration Number: NCT00000673

Locations: 🇺🇸
Univ. of Miami AIDS CRS, Miami, Florida, United States
🇺🇸
Washington U CRS, Saint Louis, Missouri, United States

Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS

Phase 2

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 167

Registration Number: NCT00001061

Locations: 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸
Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
🇺🇸
Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States

and more 17 locations

Islet Transplantation for Type 1 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Insulin-Dependent

Interventions: Procedure: Islet Transplantation
Drug: Sirolimus
Drug: Tacrolimus
Drug: Daclizumab
Drug: Sulfamethoxazole
Drug: Ganciclovir
Drug: Trimethoprim
Drug: Pentamidine

First Posted Date: 2001-08-31

Last Posted Date: 2017-03-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT00014911

Locations: 🇩🇪
Justus-Leibig University, Giessen, Germany
🇨🇦
University of Alberta, Edmonton, Alberta, Canada
🇨🇭
University of Geneva, Geneva, Switzerland

and more 6 locations

A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

Phase 3

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2017-05-17

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT00002377

Locations: 🇺🇸
Univ of California / San Diego / Dept of Pediatrics, La Jolla, California, United States
🇺🇸
St Luke's - Roosevelt Hosp Ctr / Div of Infect Dis, New York, New York, United States
🇺🇸
New York Hosp - Cornell Med Ctr, New York, New York, United States

and more 16 locations

A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients

Phase 1

Completed

Conditions: HIV Infections
Colitis

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT00000768

Locations: 🇺🇸
Alabama Therapeutics CRS, Birmingham, Alabama, United States
🇺🇸
Washington U CRS, Saint Louis, Missouri, United States
🇺🇸
Univ. of Cincinnati CRS, Cincinnati, Ohio, United States

and more 2 locations

A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With Ganciclovir

Phase 1

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 30

Registration Number: NCT00000970

Locations: 🇺🇸
Ucsf Aids Crs, San Francisco, California, United States
🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸
Washington U CRS, Saint Louis, Missouri, United States

and more 3 locations

A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection

Not Applicable

Completed

Conditions: Cytomegalovirus Infections
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 60

Registration Number: NCT00000995

Locations: 🇺🇸
Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States
🇺🇸
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸
Univ of Rochester Medical Center, Rochester, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy